



January 17, 2020

## CALL FOR APPLICATIONS - DRAFT

**Applications are due Monday, January 27, 2020, by 11:59 PM ET to**  
**<https://htrs.smapply.org>**

**VON WILLEBRAND DISEASE – FROM THEORY TO CLINICAL PRACTICE**  
**Lund University Commissioned Education | Centre for Thrombosis and Haemostasis**  
**Wednesday, April 22 - Friday, April 24, 2020**  
**Malmö, Sweden**

**The 12<sup>th</sup> international, case-oriented course offering hematologists further training in  
von Willebrand Disease**

The Hemostasis and Thrombosis Research Society (HTRS) is commissioned by Octapharma to recruit and select up to three U.S. hematologists in 2020 to attend *Von Willebrand Disease – From Theory to Clinical Practice* from April 22-24, 2020, in Malmö, Sweden. This educational course is supported by Octapharma and offered in collaboration with the Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital.

HTRS is now accepting applications from U.S. hematologists within seven years of fellowship who can demonstrate a need for further training in the diagnosis and management of VWD. Successful applicants will travel to Malmö, Sweden from April 22-24, 2020 to take part in this educational course.

**Course Title:** “VON WILLEBRAND DISEASE – FROM THEORY TO CLINICAL PRACTICE”

**Dates:** Wednesday, April 22, to Friday, April 24, 2020

**Venue:** Hotel Scandic Triangeln in Malmö, Sweden

**Program Format:** This course uses an evidence-based, interactive approach to learning through presentations and case reviews. Participants will be expected to share their experiences in the field. LIPUS, the Institute for the Professional Development of Physicians in Sweden, will review the course ([www.lipus.se](http://www.lipus.se)).

---

Hemostasis and Thrombosis Research Society, Inc.  
PO Box 2178, Milwaukee, WI 53201-2178  
8733 Watertown Plank Road, Milwaukee, WI 53226-3548  
(414) 937-6569 Fax (414) 937-3864 [www.htrs.org](http://www.htrs.org) htrs@versiti.org

**Program Description:** The 3-day course begins Wednesday morning, April 22 at 9:30 a.m. with an introduction to VWD through a series of overview lectures. Afterward, faculty will present clinical cases and discuss the management, prognosis, treatment, and diagnosis of the disease throughout the day, concluding with a dinner at 7:30 p.m.

On Thursday, April 23, case study reviews will begin at 8:30 a.m. with individual study groups to support a team-based learning approach, followed by additional lectures and the presentations of submitted abstracts until 4:30 p.m.

Friday's agenda begins with further presentations of submitted abstracts at 8:30 a.m. and continues with the course exam and awards, concluding with an optional lab visit at 1:00 p.m.

## Applicant Eligibility Requirements

This course is open to U.S. hematologists working in non-commercial institutions within seven years of fellowship whose careers demonstrate a commitment to hemostasis. Successful applicants will be able to demonstrate some previous clinical experience with VWD and explain why additional training will benefit their careers. Good English-speaking skills are required.

**Priority will be given to applicants who are current HTRS Core members. To become an HTRS Core member, visit [www.HTRS.org](http://www.HTRS.org).**

## Expected Outcomes for Course Participants

The scientific content and educational delivery methods for this course are designed by international experts in VWD, including members of the Malmö VWD faculty such as Erik Berntorp (Malmö, Sweden), Augusto Federici (Milan, Italy), Anne Goodeve (Sheffield, UK), Nadine Gretenkort Andersson (Sweden), Pål André Holme (Norway), Carolyn Millar (London, UK), Reinhard Schneppenheim (Hamburg, Germany), Karin Strandberg (Malmö, Sweden), and Eva Zetterberg (Malmö, Sweden).

Course participants should expect to acquire new knowledge in the pathophysiology and diagnoses of von Willebrand Disease. They will learn optimal ways to apply this knowledge to diagnose and treat patients at an early stage, including how to approach complications, enhance patients' quality of life, and improve their ability to take part in social activities. Ethical and socio-economic aspects of treating patients with VWD will also be discussed.

Specifically, attendees will gain new knowledge in these areas:

- Molecular genetic background
- Blood coagulation and methods of measurement
- Diagnosis
- On-demand treatment and prophylaxis
- Treatment during surgical operation
- Children with VWD and aspects of VWD in the area of gynecology and obstetrics
- Inhibitor development to VWF
- Monitoring of VWD patients
- International knowledge about organizations focused on von Willebrand Disease

Further, international guidelines for the management of VWD will be distributed. Participants will receive a course binder including guidelines, articles and lectures, and critical take-home messages.

## Application Deadline and Submission Instructions

Interested hematologists within seven years of fellowship who can demonstrate previous clinical experience with VWD must apply **on or before Monday, January 27, 2020 by 11:59 p.m. ET. Applications should be submitted via our online grant submission site: <https://htrs.smapply.org>.** Applicants should click on "Register" in the upper right corner of the home page and create an account with a username/email and password. (The site allows you to save your work and return to it later.) Then, find the von Willebrand Disease Program 2020 and begin the process.

## Application Components

1. **Application Form.** For the official required form, please email [htrs@bcw.edu](mailto:htrs@bcw.edu).
2. **Biographical Statement – 500 words or less.** The applicant should provide a biographical statement explaining his or her professional background, education, and career path in hemostasis, including previous clinical experience with VWD.
3. **Rationale for Attending – 500 words or less.** The applicant should explain why attending the course is important to his or her clinical practice and career development in hemostasis.
4. **Mentor Recommendation – 100 words or less.** The applicant's mentor should support the applicant's stated career path and explain why the applicant is a good candidate to participate in the course.
5. **Applicant's NIH Biosketch or Curriculum Vitae**

## Notification of Acceptance

All applications will be reviewed by the HTRS Malmö VWD Course Selection Committee immediately following the January 27, 2020 deadline. Applicants will be notified of acceptance via email on or before Tuesday, February 5, 2020. **Registration for the conference is due Friday, February 14, 2020.**

## Covered Expenses

The following expenses will be covered by Octapharma for confirmed course attendees:

1. **Course Registration Fee**
2. **Travel.** Reimbursement will be provided with original receipts for the cost of:
  - Round-trip, business class airline ticket booked by the attendee through the Octapharma travel agent (includes fare and change fee, if incurred). The cost of the ticket should not exceed \$8,000.00.
  - Ground transportation from the airport to the hotel and back
  - Meals on travel days
3. **Lodging.** Reimbursement will be provided for a sleeping room booked by the attendee at the course hotel indicated during registration for the nights of Tuesday, April 21, Wednesday, April 22, Thursday, April 23, and Friday, April 24. Additional nights are at the attendee's own expense.
4. **Meals.** The following meals will be provided during the course: lunch and dinner on Wednesday, April 22, lunch on Thursday, April 23, and lunch on Friday, April 24, 2020. Octapharma will reimburse for meals not included in the course and on travel days.

## **Disclosure of HTRS Compliance and Reporting Under *Open Payments: The Physician Payments Sunshine Act***

This educational activity is reportable by law under *Open Payments: The Physician Payments Sunshine Act* (“Sunshine Act”). HTRS is required to share information about participating physician attendees with the pharmaceutical company supporter, which deems this information reportable per its policies related to the Sunshine Act.

Applicants are required to confirm that their respective institutions allow them to attend educational events subject to Sunshine Act reporting, since regulations can differ by institution and state.

If you have questions about the Sunshine Act as it pertains to this educational activity, please contact HTRS at [htrs@versiti.org](mailto:htrs@versiti.org).

### **Course Supporters**

“Von Willebrand Disease – From Theory to Clinical Practice,” is supported by Octapharma. U.S. attendees’ expenses are also covered by Octapharma. HTRS administers the attendee recruitment and selection process.

### **HTRS Mission**

Incorporated as a nonprofit in 1994, HTRS is a North American professional medical society dedicated to advancing care for people with bleeding and thrombotic disorders through investigator-initiated research, mentoring, and continuing medical education. For information on HTRS educational and grant opportunities in non-malignant hematology, visit [www.htrs.org](http://www.htrs.org).

### **Questions**

For questions and additional information, please contact:

Jennifer Ziegler

Director, Awards Programs and Marketing

Hemostasis and Thrombosis Research Society

(414) 477-6130

[jziegler@versiti.org](mailto:jziegler@versiti.org)

We look forward to hearing from our future leaders in hematology!

Sincerely,

Robert F. Sidonio Jr., MD, MSc

Chair, Malmö VWD Course Selection Committee

Emory University